Managed Care
Disease
Management

 

October 2014

Costs are rising as physicians order more of all kinds of tests, from low-cost routine tests to high-cost genetic assays
Joseph Burns
The company bets that forging stronger ties with patients will result in more appropriate utilization
Susan Worley
More studies can help health plans identify what works — and what doesn’t — in different models, says this Rand researcher
John Marcille
Prices can be hard to swallow in this fastest-growing segment of the pharmaceutical market, but these approaches might help
Richard Mark Kirkner
Anonymized patient-level longitudinal data better supports formulary policy and coverage decisions, the authors say



Departments
Legislation & Regulation
They want to make it impossible for insurers to change provider networks after the enrollment period
Richard Mark Kirkner
Medication Management
PGX testing improves therapy oversight by predicting nonresponders
and identifying patients at risk for adverse drug responses
Thomas Reinke
The Formulary Files
Krishna Rutvij Patel, PharmD
ACO Update
Savings generated by the CMS program are not impressive, but quality measures show improvement
Peter Wehrwein
Medical Device Monitor
Katherine T. Adams
Tomorrow’s Medicine
Cologuard is no substitute for colonoscopy for high-risk patients, but if this new tool means more people get screened, it could save lives
Thomas Morrow, MD